Mizuho analyst Anthony Petrone lowered the firm’s price target on Staar Surgical to $45 from $50 and keeps a Buy rating on the shares. With 2024 off to a slower start versus the 2026 targets, key debates will remain on timing and extent of a China rebound amid 2025 competition, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
